NCT04472611View on ClinicalTrials.gov

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
SARS-CoV-2
Interventions
DRUG

Standard of Care (SOC) and Colchicine+Rosuvastatin

Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization

Trial Locations (4)

06610

Bridgeport Hospital, Bridgeport

06807

Greenwich Hospital, Greenwich

06512

Yale New Haven Hosptial System, New Haven

06320

Lawrence & Memorial Hospital, New London

All Listed Sponsors
lead

Yale University

OTHER

NCT04472611 - Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial | Biotech Hunter | Biotech Hunter